View Filing Data

Document And Entity Information - shares	6 Months Ended
Document And Entity Information - shares	Jun. 30, 2019	Aug. 10, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Registrant Name	OPGEN INC
Entity Central Index Key	0001293818
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Trading Symbol	OPGN
Entity Common Stock, Shares Outstanding		17,645,720
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-37367
Entity Tax Identification Number	061614015
Entity Address, Address Line One	708 Quince Orchard Road
Entity Address, Address Line Two	Suite 205
Entity Address, City or Town	Gaithersburg
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20878
City Area Code	240
Local Phone Number	813-1260

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 3,055,894	$ 4,572,487
Accounts receivable, net	772,914	373,858
Inventory, net	567,422	543,747
Prepaid expenses and other current assets	178,356	292,918
Total current assets	4,574,586	5,783,010
Property and equipment, net	197,502	1,221,827
Finance lease right-of-use assets, net	984,742	0
Operating lease right-of-use assets	1,381,830	0
Goodwill	600,814	600,814
Intangible assets, net	951,458	1,085,366
Other noncurrent assets	241,182	259,346
Total assets	8,932,114	8,950,363
Current liabilities
Accounts payable	1,258,908	1,623,751
Accrued compensation and benefits	1,190,500	1,041,573
Accrued liabilities	820,667	902,019
Deferred revenue	9,993	15,824
Short-term notes payable	343,330	398,595
Short-term finance lease liabilities	576,322	399,345
Short-term operating lease liabilities	958,992	0
Total current liabilities	5,158,712	4,381,107
Deferred rent	0	162,919
Note payable	494,897	660,340
Warrant liability	0	67
Long-term finance lease liabilities	379,825	437,189
Long-term operating lease liabilities	1,071,677	0
Total liabilities	7,105,111	5,641,622
Commitments (Note 9)
Stockholders' equity
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at June 30, 2019 and December 31, 2018, respectively	0	0
Common stock, $0.01 par value; 50,000,000 shares authorized; 17,645,720 and 8,645,720 shares issued and outstanding at June 30, 2019 and December 31, 2018, respectively	176,457	86,457
Additional paid-in capital	170,190,415	165,313,902
Accumulated deficit	(168,524,652)	(162,078,525)
Accumulated other comprehensive loss	(15,217)	(13,093)
Total stockholders’ equity	1,827,003	3,308,741
Total liabilities and stockholders’ equity	$ 8,932,114	$ 8,950,363

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	17,645,720	8,645,720
Common stock, shares outstanding	17,645,720	8,645,720
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Revenue
Total revenue	$ 1,009,543	$ 788,901	$ 2,029,720	$ 1,635,127
Operating expenses
Research and development	1,153,584	1,304,388	2,929,966	2,534,817
General and administrative	1,592,845	1,831,063	3,340,430	3,621,585
Sales and marketing	393,567	426,297	765,800	756,070
Impairment of right-of-use asset	0	0	520,759	0
Total operating expenses	3,590,470	4,044,813	8,372,613	7,906,922
Operating loss	(2,580,927)	(3,255,912)	(6,342,893)	(6,271,795)
Other (expense) income
Other income (expense)	15,166	5	(9,256)	5,303
Interest expense	(37,129)	(54,533)	(93,573)	(112,379)
Foreign currency transaction gains (losses)	9,879	(21,762)	(472)	(9,581)
Change in fair value of derivative financial instruments	0	(11)	67	8,155
Total other expense	(12,084)	(76,301)	(103,234)	(108,502)
Loss before income taxes	(2,593,011)	(3,332,213)	(6,446,127)	(6,380,297)
Provision for income taxes	0	0	0	0
Net loss	(2,593,011)	(3,332,213)	(6,446,127)	(6,380,297)
Net loss available to common stockholders	$ (2,593,011)	$ (3,332,213)	$ (6,446,127)	$ (6,380,297)
Net loss per common share - basic and diluted	$ (0.15)	$ (0.57)	$ (0.48)	$ (1.29)
Weighted average shares outstanding - basic and diluted	17,645,720	5,826,947	13,518,648	4,950,517
Net loss	$ (2,593,011)	$ (3,332,213)	$ (6,446,127)	$ (6,380,297)
Other comprehensive (loss) gain - foreign currency translations	(4,950)	18,113	(2,124)	5,534
Comprehensive loss	(2,597,961)	(3,314,100)	(6,448,251)	(6,374,763)
Product [Member]
Revenue
Total revenue	504,293	632,525	1,024,470	1,266,021
Operating expenses
Cost of products and services	198,493	303,663	419,195	646,495
Laboratory Service Revenue [Member]
Revenue
Total revenue	5,250	1,100	5,250	9,790
Collaborations Revenue [Member]
Revenue
Total revenue	500,000	155,276	1,000,000	359,316
Service [Member]
Operating expenses
Cost of products and services	$ 251,981	$ 179,402	$ 396,463	$ 347,955

Condensed Consolidated Statements of Stockholders' Equity - USD ($)	Total	Public Offering [Member]	At the Market Offering [Member]	Common Stock [Member]	Common Stock [Member] Public Offering [Member]	Common Stock [Member] At the Market Offering [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] Public Offering [Member]	Additional Paid-in Capital [Member] At the Market Offering [Member]	Accumulated Other Comprehensive Loss [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2017	$ 1,400,997			$ 22,653			$ 150,114,671			$ (25,900)	$ (148,710,427)
Balance (in shares) at Dec. 31, 2017				2,265,320
Issuance of units, net of offering costs		$ 10,721,400			$ 30,192			$ 10,691,208
Issuance of units, net of offering costs (in shares)					3,019,230
Issuance of RSUs				$ 54			(54)
Issuance of RSUs (in shares)				5,400
Stock compensation expense	238,190						238,190
Stock cancellation (in shares)				(31)
Foreign currency translation	(12,579)									(12,579)
Net loss	(3,048,084)										(3,048,084)
Balance at Mar. 31, 2018	9,299,924			$ 52,899			161,044,015			(38,479)	(151,758,511)
Balance (in shares) at Mar. 31, 2018				5,289,919
Balance at Dec. 31, 2017	1,400,997			$ 22,653			150,114,671			(25,900)	(148,710,427)
Balance (in shares) at Dec. 31, 2017				2,265,320
Net loss	(6,380,297)
Balance at Jun. 30, 2018	6,398,765			$ 60,670			161,449,185			(20,366)	(155,090,724)
Balance (in shares) at Jun. 30, 2018				6,067,039
Balance at Dec. 31, 2017	1,400,997			$ 22,653			150,114,671			(25,900)	(148,710,427)
Balance (in shares) at Dec. 31, 2017				2,265,320
Balance at Dec. 31, 2018	3,308,741			$ 86,457			165,313,902			(13,093)	(162,078,525)
Balance (in shares) at Dec. 31, 2018				8,645,720
Balance at Mar. 31, 2018	9,299,924			$ 52,899			161,044,015			(38,479)	(151,758,511)
Balance (in shares) at Mar. 31, 2018				5,289,919
Issuance of units, net of offering costs		6,731	$ 192,320		$ 6,731	$ 1,040			$ 191,280
Issuance of units, net of offering costs (in shares)					673,077	104,043
Stock compensation expense	213,890						213,890
Foreign currency translation	18,113									18,113
Net loss	(3,332,213)										(3,332,213)
Balance at Jun. 30, 2018	6,398,765			$ 60,670			161,449,185			(20,366)	(155,090,724)
Balance (in shares) at Jun. 30, 2018				6,067,039
Balance at Dec. 31, 2018	3,308,741			$ 86,457			165,313,902			(13,093)	(162,078,525)
Balance (in shares) at Dec. 31, 2018				8,645,720
Issuance of units, net of offering costs		$ 4,782,509			$ 90,000			$ 4,692,509
Issuance of units, net of offering costs (in shares)					9,000,000
Stock compensation expense	98,033						98,033
Foreign currency translation	2,826									2,826
Net loss	(3,853,116)										(3,853,116)
Balance at Mar. 31, 2019	4,338,993			$ 176,457			170,104,444			(10,267)	(165,931,641)
Balance (in shares) at Mar. 31, 2019				17,645,720
Balance at Dec. 31, 2018	3,308,741			$ 86,457			165,313,902			(13,093)	(162,078,525)
Balance (in shares) at Dec. 31, 2018				8,645,720
Net loss	(6,446,127)
Balance at Jun. 30, 2019	1,827,003			$ 176,457			170,190,415			(15,217)	(168,524,652)
Balance (in shares) at Jun. 30, 2019				17,645,720
Balance at Mar. 31, 2019	4,338,993			$ 176,457			170,104,444			(10,267)	(165,931,641)
Balance (in shares) at Mar. 31, 2019				17,645,720
Stock compensation expense	85,971						85,971
Foreign currency translation	(4,950)									(4,950)
Net loss	(2,593,011)										(2,593,011)
Balance at Jun. 30, 2019	$ 1,827,003			$ 176,457			$ 170,190,415			$ (15,217)	$ (168,524,652)
Balance (in shares) at Jun. 30, 2019				17,645,720

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Cash flows from operating activities
Net loss			$ (6,446,127)	$ (6,380,297)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization			450,952	317,652
Noncash interest expense			43,371	94,594
Stock compensation expense			184,004	452,080
Loss (gain) on sale of equipment			9,904	(5,253)
Change in fair value of warrant liability			(67)	(8,155)
Impairment of right-of-use asset	$ 0	$ 0	520,759	0
Changes in operating assets and liabilities:
Accounts receivable			(399,528)	291,273
Inventory			(23,824)	(81,321)
Other assets			429,558	(235,835)
Accounts payable			(301,376)	(219,565)
Accrued compensation and other liabilities			(285,953)	226,611
Deferred revenue			(5,831)	(10,320)
Net cash used in operating activities			(5,824,158)	(5,558,536)
Cash flows from investing activities
Purchases of property and equipment			(24,680)	(4,457)
Proceeds from sale of equipment			29,250	10,440
Net cash provided by investing activities			4,570	5,983
Cash flows from financing activities
Proceeds from issuance of common stock, net of issuance costs			4,782,509	192,320
Proceeds from issuance of units, net of selling costs			0	10,728,131
Proceeds from debt, net of issuance costs			15,481	309,900
Payments on debt			(237,414)	(55,582)
Payments on finance leases			(235,600)	(107,871)
Net cash provided by financing activities			4,324,976	11,066,898
Effects of exchange rates on cash			(1,321)	5,587
Net (decrease) increase in cash, cash equivalents and restricted cash			(1,495,933)	5,519,932
Cash, cash equivalents and restricted cash at beginning of period			4,737,207	2,090,551	$ 2,090,551
Cash, cash equivalents and restricted cash at end of period	$ 3,241,274	$ 7,610,483	3,241,274	7,610,483	$ 4,737,207
Supplemental disclosure of cash flow information
Cash paid for interest			97,599	17,785
Supplemental disclosures of noncash investing and financing activities:
Right-of-use assets acquired through finance leases			291,936	281,153
Conversion of accounts payable to finance lease			$ 63,600	$ 174,968

Organization

6 Months Ended

Jun. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Organization

Note 1 – Organization

OpGen, Inc. (“OpGen” or the “Company”) was incorporated in Delaware in 2001. References in this report to the “Company” include OpGen and its wholly-owned subsidiaries. The Company’s headquarters and its principal operations are in Gaithersburg, Maryland. The Company also has operations in Copenhagen, Denmark, and Bogota, Colombia. The Company operates in one business segment.

OpGen is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. The Company is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections.

The Company’s molecular diagnostics and informatics products, product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its proprietary, curated MDRO knowledgebase. The Company is working to deliver products and services, some in development, to a global network of customers and partners.

•

The Company’s Acuitas molecular diagnostic tests provide rapid microbial identification and antibiotic resistance gene information. These products include its Acuitas antimicrobial resistance, or AMR, Gene Panel (Urine) test in development for patients at risk for complicated urinary tract infection, or cUTI, and its Acuitas AMR Gene Panel (Isolates) test in development for testing bacterial isolates, and its QuickFISH and PNA FISH FDA-cleared and CE-marked diagnostics used to rapidly detect pathogens in positive blood cultures. Each of the Acuitas AMR Gene Panel tests is available for sale for research use only, or RUO.

•

The Company’s Acuitas Lighthouse informatics systems are cloud-based HIPAA compliant informatics offerings that combine clinical lab test results with patient and hospital information to provide analytics and actionable insights to help manage MDROs in the hospital and patient care environment. Components of the informatics systems include the Acuitas Lighthouse Knowledgebase and the Acuitas Lighthouse Software. The Acuitas Lighthouse Knowledgebase is a relational database management system and a proprietary data warehouse of genomic data matched with antibiotic susceptibility information for bacterial pathogens. The Acuitas Lighthouse Software system includes the Acuitas Lighthouse Portal, a suite of web applications and dashboards, the Acuitas Lighthouse Prediction Engine, which is a data analysis software, and other supporting software components. The Acuitas Lighthouse Software can be customized and made specific to a healthcare facility or collaborator, such as a pharmaceutical company. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures.

The Company’s operations are subject to certain risks and uncertainties. The risks include the risk that the Company will not receive 510(k) clearance for its Acuitas AMR Gene Panel tests and Acuitas Lighthouse Software on a timely basis, or at all, rapid technology changes, the need to retain key personnel, the need to protect intellectual property and the need to raise additional capital financing on terms acceptable to the Company. The Company’s success depends, in part, on its ability to develop, obtain regulatory approval for and commercialize its proprietary technology as well as raise additional capital.

Liquidity and management's plans

6 Months Ended

Jun. 30, 2019

Liquidation Basis Of Accounting Abstract [Abstract]

Liquidity and management's plans

Note 2 – Liquidity and management’s plans

The accompanying unaudited condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Since inception, the Company has incurred, and continues to incur, significant losses from operations. The Company has funded its operations primarily through external investor financing transactions, including the following in 2018 and 2019 to date:

•

On March 29, 2019, the Company closed a public offering (the “March 2019 Public Offering”) of 9,000,000 shares of its common stock at a public offering price of $0.60 per share. The offering raised gross proceeds of $5.4 million and net proceeds of approximately $4.8 million.

•

On October 22, 2018, the Company closed a public offering (the “October 2018 Public Offering”) of 2,220,000 shares of its common stock at a public offering price of $1.45 per share. The offering raised gross proceeds of approximately $3.2 million and net proceeds of approximately $2.8 million.

•

On June 11, 2018, the Company executed an Allonge (the “Allonge”) to its Second Amended and Restated Senior Secured Promissory Note, dated June 28, 2017, with a principal amount of $1,000,000 issued to Merck Global Health Innovation Fund, LLC (“MGHIF”). The Allonge provided that accrued and unpaid interest of $285,512 due as of July 14, 2018, the original maturity date, be paid through the issuance of shares of OpGen’s common stock in a private placement transaction. In addition, the Allonge revised and extended the maturity date for payment of the Promissory Note to six semi-annual payments of $166,667 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021. On July 30, 2018, the Company issued 144,238 shares of common stock to MGHIF in a private placement transaction for $285,512 of accrued and unpaid interest due as of July 14, 2018 under the MGHIF Note.

•

On February 6, 2018, the Company closed a public offering (the “February 2018 Public Offering”) of 2,841,152 units at $3.25 per unit, and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million and net proceeds of approximately $10.7 million. Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. The common warrants are exercisable immediately and have a five-year term from the date of issuance. The 851,155 pre-funded warrants issued in the February 2018 Public Offering were exercised during the year ended December 31, 2018.

•

On September 13, 2016, the Company entered into the Sales Agreement (the “Sales Agreement”) with Cowen and Company LLC (“Cowen”) pursuant to which the Company could offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. During the year ended December 31, 2018, the Company sold 318,236 shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $0.6 million, and gross proceeds of $0.6 million. The at the market offering was terminated in connection with the October 2018 Public Offering.

To meet its capital needs, the Company is considering multiple alternatives, including, but not limited to, strategic financings or other transactions, additional equity financings, debt financings and other funding transactions, licensing and/or partnering arrangements and business combination transactions. There can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The Company believes that current cash will be sufficient to fund operations into the third quarter of 2019. This has led management to conclude that substantial doubt about the Company’s ability to continue as a going concern exists. In the event the Company is unable to successfully raise additional capital during or before the end of the third quarter of 2019, the Company will not have sufficient cash flows and liquidity to finance its business operations as currently contemplated. Accordingly, in such circumstances the Company would be compelled to immediately reduce general and administrative expenses and delay research and development projects, including the purchase of scientific equipment and supplies, until it is able to obtain sufficient financing. If such sufficient financing is not received on a timely basis, the Company would then need to pursue a plan to license or sell its assets, seek to be acquired by another entity, cease operations and/or seek bankruptcy protection.

Summary of significant accounting policies

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Summary of significant accounting policies

Note 3 – Summary of significant accounting policies

Basis of presentation and consolidation

The Company has prepared the accompanying unaudited condensed consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and the standards of accounting measurement set forth in the Interim Reporting Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”). Certain information and note disclosures normally included in annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) have been condensed or omitted, although the Company believes that the disclosures made are adequate to make the information not misleading. The Company recommends that the unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and the notes thereto included in the Company’s 2018 Annual Report on Form 10-K. In the opinion of management, all adjustments that are necessary for a fair presentation of the Company’s financial position for the periods presented have been reflected. All adjustments are of a normal, recurring nature, unless otherwise stated. The interim condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2018 consolidated balance sheet included herein was derived from the audited consolidated financial statements, but does not include all disclosures including notes required by GAAP for complete financial statements.

The accompanying unaudited condensed consolidated financial statements include the accounts of OpGen and its wholly-owned subsidiaries; all intercompany transactions and balances have been eliminated.

Foreign currency

The Company has subsidiaries located in Copenhagen, Denmark, and Bogota, Colombia, both of which use currencies other than the U.S dollar as their functional currency. As a result, all assets and liabilities are translated into U.S. dollars based on exchange rates at the end of the reporting period. Income and expense items are translated at the average exchange rates prevailing during the reporting period. Translation adjustments are reported in accumulated other comprehensive loss, a component of stockholders’ equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at June 30, 2019 and December 31, 2018.

Foreign currency transaction gains and losses, excluding gains and losses on intercompany balances where there is no current intent to settle such amounts in the foreseeable future, are included in the determination of net loss. Unless otherwise noted, all references to “$” or “dollar” refer to the U.S. dollar.

Use of estimates

In preparing financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In the accompanying unaudited condensed consolidated financial statements, estimates are used for, but not limited to, liquidity assumptions, revenue recognition, stock-based compensation, allowances for doubtful accounts and inventory obsolescence, discount rates used to discount unpaid lease payments to present values, valuation of derivative financial instruments measured at fair value on a recurring basis, deferred tax assets and liabilities and related valuation allowance, the estimated useful lives of long-lived assets, and the recoverability of long-lived assets. Actual results could differ from those estimates.

Fair value of financial instruments

Financial instruments classified as current assets and liabilities (including cash and cash equivalent, receivables, accounts payable, deferred revenue and short-term notes) are carried at cost, which approximates fair value, because of the short-term maturities of those instruments.

Cash, cash equivalents and restricted cash

The Company considers all highly liquid instruments with original maturities of three months or less to be cash equivalents. The Company has cash and cash equivalents deposited in financial institutions in which the balances occasionally exceed the federal government agency (“FDIC”) insured limit of $250,000. The Company has not experienced any losses in such accounts and management believes it is not exposed to any significant credit risk.

At June 30, 2019, the Company has funds totaling $185,380, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. At December 31, 2018, the Company had funds totaling $164,720, which are required as collateral for letters of credit benefiting its landlords and for credit card processors. These funds are reflected in other noncurrent assets on the accompanying unaudited condensed consolidated balance sheets.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows:

	June 30, 2019		December 31, 2018		June 30, 2018		December 31, 2017
Cash and cash equivalents	$	3,055,894	$	4,572,487	$	7,428,993	$	1,847,171
Restricted cash		185,380		164,720		181,490		243,380
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	$	3,241,274	$	4,737,207	$	7,610,483	$	2,090,551

Accounts receivable

The Company’s accounts receivable result from revenues earned but not yet collected from customers. Credit is extended based on an evaluation of a customer’s financial condition and, generally, collateral is not required. Accounts receivable are due within 30 to 60 days and are stated at amounts due from customers. The Company evaluates if an allowance is necessary by considering a number of factors, including the length of time accounts receivable are past due, the Company’s previous loss history and the customer’s current ability to pay its obligation. If amounts become uncollectible, they are charged to operations when that determination is made. The allowance for doubtful accounts was $22,309 and $18,332 as of June 30, 2019 and December 31, 2018, respectively.

One individual customer represented 50% and 19% of revenues for the three months ended June 30, 2019 and 2018, respectively. One individual customer represented 49% and 21% of revenues for the six months ended June 30, 2019 and 2018, respectively. At June 30, 2019, one individual customer represented 65% of total accounts receivable. At December 31, 2018, one individual customer represented 12% of total accounts receivable.

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials and supplies	$	237,500	$	368,438
Work-in-process		135,916		58,402
Finished goods		194,006		116,907
Total	$	567,422	$	543,747

Inventory includes reagents and components for QuickFISH and PNA FISH kit products, and reagents and supplies used for the Company’s laboratory services. Inventory reserves for obsolescence and expirations were $114,327 and $71,270 at June 30, 2019 and December 31, 2018, respectively.

Long-lived assets

Property and equipment

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which we can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. During the three and six months ended June 30, 2019 and 2018, the Company determined that its property and equipment was not impaired.

Leases

The Company determines if an arrangement is a lease at inception. For leases where the Company is the lessee, right-of-use (“ROU”) assets represent the Company’s right to use the underlying asset for the term of the lease and the lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of the future lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at the commencement date of the underlying lease arrangement to determine the present value of lease payments. The ROU asset also includes any prepaid lease payments and any lease incentives received. The lease term to calculate the ROU asset and related lease liability includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise the option. The Company’s lease agreements generally do not contain any material variable lease payments, residual value guarantees or restrictive covenants.

Lease expense for operating leases is recognized on a straight-line basis over the lease term as an operating expense while expense for financing leases is recognized as depreciation expense and interest expense using the accelerated interest method of recognition. The Company has made certain accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases.

ROU assets

ROU assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. Recoverability measurement and estimating of undiscounted cash flows is done at the lowest possible level for which the Company can identify assets. If such assets are considered to be impaired, impairment is recognized as the amount by which the carrying amount of assets exceeds the fair value of the assets. In conjunction with adoption of Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842) (“ASC 842”), the Company determined that the ROU asset associated with its Woburn, Massachusetts office lease may not be recoverable. As a result, the Company recorded an impairment charge of $520,759 during the six months ended June 30, 2019.

Intangible assets and goodwill

Intangible assets and goodwill as of June 30, 2019 consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of June 30, 2019 and December 31, 2018:

			June 30, 2019					December 31, 2018
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and trade names	$	461,000	$	(182,835	)	$	278,165	$	(159,783	)	$	301,217
Developed technology		458,000		(259,458	)		198,542		(226,746	)		231,254
Customer relationships		1,094,000		(619,249	)		474,751		(541,105	)		552,895
	$	2,013,000	$	(1,061,542	)	$	951,458	$	(927,634	)	$	1,085,366

Finite-lived intangible assets are amortized over their estimated useful lives. The estimated useful life of trademarks is 10 years, developed technology is 7 years, and customer relationships is 7 years. The Company reviews the useful lives of intangible assets when events or changes in circumstances occur which may potentially impact the estimated useful life of the intangible assets.

Total amortization expense of intangible assets was $66,954 for each of the three months ended June 30, 2019 and 2018. Total amortization expense of intangible assets was $133,908 for each of the six months ended June 30, 2019 and 2018.

Finite-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. If any indicators were present, the Company would test for recoverability by comparing the carrying amount of the asset to the net undiscounted cash flows expected to be generated from the asset. If those net undiscounted cash flows do not exceed the carrying amount (i.e., the asset is not recoverable), the Company would perform the next step, which is to determine the fair value of the asset and record an impairment loss, if any. During the three and six months ended June 30, 2019 and 2018, the Company determined that its finite-lived intangible assets were not impaired.

In accordance with ASC 360-10, Property, Plant and Equipment, the Company records impairment losses on long-lived assets used in operations when events and circumstances indicate that long-lived assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are less than the carrying amounts of those assets. During the fourth quarter of 2018, events and circumstances indicated the Company’s intangible assets might be impaired. However, management’s estimate of undiscounted cash flows indicated that such carrying amounts were expected to be recovered. Nonetheless, it is reasonably possible that the estimate of undiscounted cash flows may change in the near term resulting in the need to write down those assets to fair value. Management’s estimate of cash flows might change if there is an unfavorable development of sales trends.

Goodwill

Goodwill represents the excess of the purchase price paid in a July 2015 merger transaction in which the Company acquired AdvanDx, Inc. and its subsidiary (the “Merger”) over the fair values of the acquired tangible or intangible assets and assumed liabilities. Goodwill is not tax deductible in any relevant jurisdictions. The Company’s goodwill balance as of June 30, 2019 and December 31, 2018 was $600,814.

The Company conducts an impairment test of goodwill on an annual basis as of October 1 of each year, and will also conduct tests if events occur or circumstances change that would, more likely than not, reduce the Company’s fair value below its net equity value. During the three and six months ended June 30, 2019 and 2018, the Company determined that its goodwill was not impaired.

Revenue recognition

The Company derives revenues from (i) the sale of QuickFISH and PNA FISH diagnostic test products and Acuitas AMR Gene Panel RUO test products, (ii) providing laboratory services, and (iii) providing collaboration services including funded software arrangements, and license arrangements.

The Company analyzes contracts to determine the appropriate revenue recognition using the following steps: (i) identification of contracts with customers, (ii) identification of distinct performance obligations in the contract, (iii) determination of contract transaction price, (iv) allocation of contract transaction price to the performance obligations and (v) determination of revenue recognition based on timing of satisfaction of the performance obligation.

The Company recognizes revenues upon the satisfaction of its performance obligation (upon transfer of control of promised goods or services to our customers) in an amount that reflects the consideration to which it expects to be entitled in exchange for those goods or services.

The Company defers incremental costs of obtaining a customer contract and amortizes the deferred costs over the period that the goods and services are transferred to the customer. The Company had no material incremental costs to obtain customer contracts in any period presented.

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

Research and development costs

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and related expenses for personnel, other resources, laboratory supplies, and fees paid to consultants and outside service partners.

Stock-based compensation

Stock-based compensation expense is recognized at fair value. The fair value of stock-based compensation to employees and directors is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. For all time-vesting awards granted, expense is amortized using the straight-line attribution method. The Company accounts for forfeitures as they occur.

Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the expected future tax consequences attributable to temporary differences between financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is established when necessary to reduce deferred income tax assets to the amount expected to be realized.

Tax benefits are initially recognized in the financial statements when it is more likely than not the position will be sustained upon examination by the tax authorities. Such tax positions are initially, and subsequently, measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement with the tax authority, assuming full knowledge of the position and all relevant facts.

The Company had federal net operating loss (“NOL”) carryforwards of $178.2 million at December 31, 2018. Despite the NOL carryforwards, which begin to expire in 2022, the Company may have future tax liability due to alternative minimum tax or state tax requirements. Also, use of the NOL carryforwards may be subject to an annual limitation as provided by Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”). To date, the Company has not performed a formal study to determine if any of its remaining NOL and credit attributes might be further limited due to the ownership change rules of Section 382 or Section 383 of the Code. The Company will continue to monitor this matter going forward. There can be no assurance that the NOL carryforwards will ever be fully utilized.

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

For periods of net income, and when the effects are not anti-dilutive, diluted earnings per share is computed by dividing net income available to common stockholders by the weighted average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options and stock purchase warrants using the treasury stock method, and convertible preferred stock and convertible debt using the if-converted method.

For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all dilutive potential common shares is anti-dilutive. The number of anti-dilutive shares, consisting of (i) common stock options, (ii) stock purchase warrants, and (iii) restricted stock units representing the right to acquire shares of common stock which have been excluded from the computation of diluted loss per share, was 4.0 million shares and 3.8 million shares as of June 30, 2019 and 2018, respectively.

Adopted accounting pronouncements

There have been no developments to the Recent Accounting Pronouncements discussion included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, including the expected dates of adoption and estimated effects on the Company’s condensed consolidated financial statements, except for the following:

In February 2016, the FASB issued ASC 842, which amends the existing accounting standards for leases. The guidance requires lessees to recognize assets and liabilities related to long-term leases on the balance sheet and expands disclosure requirements regarding leasing arrangements. The Company adopted this guidance effective January 1, 2019 using the modified retrospective transition method and the following practical expedients:

•

The Company did not reassess if any expired or existing contracts are or contain leases.

•

The Company did not reassess the classification of any expired or existing leases.

Additionally, the Company made ongoing accounting policy elections whereby the Company (i) does not recognize ROU assets or lease liabilities for short-term leases (those with original terms of 12 months or less) and (ii) combines lease and non-lease elements of our operating leases.

Upon adoption of the new guidance on January 1, 2019, the Company recorded an operating lease right of use asset of approximately $2.2 million (net of existing deferred rent) and recognized a lease liability of approximately $2.5 million.

In June 2018, the FASB issued ASU 2018-07: Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year, early adoption is permitted but no earlier than an entity’s adoption date of ASC 606. The adoption of this new guidance did not have a material impact on the Company’s condensed consolidated financial statements.

In August 2018, the SEC issued a final rule that amends certain disclosure requirements that were duplicative, outdated or superseded. In addition, the final rule expanded the financial reporting requirements for changes in stockholders’ equity for interim reporting periods. The Company adopted the new guidance on January 1, 2019 with no material impact to the condensed consolidated financial statements.

The Company has evaluated all other issued and unadopted ASUs and believes the adoption of these standards will not have a material impact on its results of operations, financial position or cash flows.

Revenue from contracts with customers

6 Months Ended

Jun. 30, 2019

Revenue From Contract With Customer [Abstract]

Revenue from contracts with customers

Note 4 – Revenue from contracts with customers

Disaggregated revenue

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Product sales	$	504,293	$	632,525	$	1,024,470	$	1,266,021
Laboratory services		5,250		1,100		5,250		9,790
Collaboration revenue		500,000		155,276		1,000,000		359,316
Total revenue	$	1,009,543	$	788,901	$	2,029,720	$	1,635,127

Deferred revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2018	$	15,824
Revenue recognized in the current period from the amounts in the beginning balance		(5,831	)
New deferrals, net of amounts recognized in the current period		—
Balance at June 30, 2019	$	9,993

Contract assets

The Company had no contract assets as of June 30, 2019, which are generated when contractual billing schedules differ from revenue recognition timing. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

Unsatisfied performance obligations

Remaining contract consideration for which revenue has not been recognized due to unsatisfied performance obligations was $575,000 at June 30, 2019, which the Company expects to recognize over the next six months.

MGHIF financing

6 Months Ended

Jun. 30, 2019

Common Stock And Note Purchase Agreement [Abstract]

MGHIF financing

Note 5 – MGHIF financing

In July 2015, in connection with the Merger, the Company entered into a Purchase Agreement with MGHIF, pursuant to which MGHIF purchased 45,454 shares of common stock of the Company at $110.00 per share for gross proceeds of $5.0 million. Pursuant to the Purchase Agreement, the Company also issued to MGHIF an 8% Senior Secured Promissory Note (the “MGHIF Note”) in the principal amount of $1.0 million with a two-year maturity date from the date of issuance. The Company’s obligations under the MGHIF Note are secured by a lien on all of the Company’s assets.

On June 28, 2017, the MGHIF Note was amended and restated, and the maturity date of the MGHIF Note was extended by one year to July 14, 2018. As consideration for the agreement to extend the maturity date, the Company issued an amended and restated secured promissory note to MGHIF that (1) increased the interest rate to ten percent (10%) per annum and (2) provided for the issuance of common stock warrants to purchase 13,120 shares of its common stock to MGHIF.

On June 11, 2018, the Company executed an Allonge to the MGHIF Note. The Allonge provided that accrued and unpaid interest of $285,512 due as of July 14, 2018, the original maturity date, be paid through the issuance of shares of OpGen’s common stock in a private placement transaction. In addition, the Allonge revised and extended the maturity date for payment of the Note to six semi-annual payments of $166,667 plus accrued and unpaid interest beginning on January 2, 2019 and ending on July 1, 2021.

On July 30, 2018, the Company issued 144,238 shares of common stock to MGHIF in a private placement transaction for $285,512 of accrued and unpaid interest due as of July 14, 2018 under the MGHIF Note.

The Allonge to the MGHIF Note was treated as a debt modification and as such the unamortized issuance costs of approximately $7,000 as of June 11, 2018 are deferred and amortized as incremental expense over the term of the MGHIF Note.

Fair value measurements

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Fair value measurements

Note 6 – Fair value measurements

The Company classifies its financial instruments using a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers include:

•

Level 1 - defined as observable inputs such as quoted prices in active markets;

•

Level 2 - defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and

•

Level 3 - defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions such as expected revenue growth and discount factors applied to cash flow projections.

For the six months ended June 30, 2019, the Company has not transferred any assets between fair value measurement levels.

Financial assets and liabilities measured at fair value on a recurring basis

The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the hierarchy.

As part of the Company’s bridge financing and amendment to the MGHIF Note, the Company issued stock purchase warrants that the Company considers to be mark-to-market liabilities due to certain put features that allow the holder to put the warrant back to the Company for cash equal to the Black-Scholes value of the warrant upon a change of control or fundamental transaction. The Company determines the fair value of the warrant liabilities using the Black-Scholes option pricing model. Using this model, level 3 unobservable inputs include the estimated volatility of the Company’s common stock, estimated terms of the instruments, and estimated risk-free interest rates.

The following table sets forth a summary of changes in the fair value of level 3 liabilities measured at fair value on a recurring basis for the six months ended June 30, 2019:

Description

Balance at

December 31,

2018

Change in

Fair Value

Balance at

June 30, 2019

Warrant liability

(67

)

—

Financial assets and liabilities carried at fair value on a non-recurring basis

The Company does not have any financial assets and liabilities measured at fair value on a non-recurring basis.

Non-financial assets and liabilities carried at fair value on a recurring basis

The Company does not have any non-financial assets and liabilities measured at fair value on a recurring basis.

Non-financial assets and liabilities carried at fair value on a non-recurring basis

The Company measures its long-lived assets, including property and equipment and intangible assets (including goodwill), at fair value on a non-recurring basis when they are deemed to be impaired. No such fair value impairment was recognized in the three and six months ended June 30, 2019 and 2018.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Debt

6 Months Ended

Jun. 30, 2019

Debt Disclosure [Abstract]

Debt

Note 7 – Debt

As of June 30, 2019, the Company’s outstanding short-term debt consisted of approximately $333,000 due under the MGHIF Note, as well as the financing arrangements for the Company’s insurance with note balances of approximately $10,000 with a final payment scheduled for February 2020. The Company’s outstanding long-term debt as of June 30, 2019 consisted of approximately $495,000 due under the MGHIF Note (see Note 5 “MGHIF financing”). As of December 31, 2018, the Company’s outstanding short-term debt consisted of $333,000 due under the MGHIF Note, net of discounts and financing costs, as well as the financing arrangements for the Company’s insurance with note balances of approximately $65,000. The Company’s outstanding long-term debt as of December 31, 2018 consisted of approximately $660,000 due under the MGHIF Note, net of discounts and financing costs. Total principal payments of approximately $333,000 are due annually in 2019, 2020, and 2021.

Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $37,129 and $54,533 for the three months ended June 30, 2019 and 2018, respectively. Total interest expense (including amortization of debt discounts and financing fees) on all debt instruments was $93,573 and $112,379 for the six months ended June 30, 2019 and 2018, respectively.

Stockholders' equity

6 Months Ended

Jun. 30, 2019

Stockholders Equity Note [Abstract]

Stockholders' equity

Note 8 – Stockholders’ equity

As of June 30, 2019, the Company has 50,000,000 authorized shares of common stock and 17,645,720 shares issued and outstanding, and 10,000,000 authorized shares of preferred stock, of which none were issued or outstanding.

In September 2016, the Company entered into the Sales Agreement with Cowen pursuant to which the Company could offer and sell from time to time, up to an aggregate of $25 million of shares of its common stock through Cowen, as sales agent, with initial sales limited to an aggregate of $11.5 million. During the year ended December 31, 2018, the Company sold 318,236 shares of its common stock under this at the market offering resulting in aggregate net proceeds to the Company of approximately $0.6 million, and gross proceeds of $0.6 million. In connection with the October 2018 Public Offering, the Company terminated the at the market offering.

In the February 2018 Public Offering, the Company issued 2,841,152 units at $3.25 per unit, and 851,155 pre-funded units at $3.24 per pre-funded unit, raising gross proceeds of approximately $12 million and net proceeds of approximately $10.7 million. Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. The common warrants were exercisable immediately and have a five-year term from the date of issuance. The 851,155 pre-funded warrants issued in the February 2018 Public Offering were exercised during the year ended December 31, 2018.

In connection with the February 2018 Public Offering, the Company issued to its placement agent warrants to purchase 184,615 shares of common stock. The warrants issued to the placement agent have an exercise price of $4.0625 per share and are exercisable for five years.

On October 22, 2018, the Company closed the October 2018 Public Offering of 2,220,000 shares of its common stock at a public offering price of $1.45 per share. The offering raised gross proceeds of approximately $3.2 million and net proceeds of approximately $2.8 million.

On March 29, 2019, the Company closed the March 2019 Public Offering of 9,000,000 shares of its common stock at a public offering price of $0.60 per share. The offering raised gross proceeds of $5.4 million and net proceeds of approximately $4.8 million.

Stock options

In 2008, the Company adopted the 2008 Stock Option and Restricted Stock Plan (the “2008 Plan”), pursuant to which the Company’s Board of Directors could grant either incentive or non-qualified stock options or shares of restricted stock to directors, key employees, consultants and advisors.

In April 2015, the Company adopted, and the Company’s stockholders approved, the 2015 Equity Incentive Plan (the “2015 Plan”); the 2015 Plan became effective upon the execution and delivery of the underwriting agreement for the Company’s initial public offering in May 2015. Following the effectiveness of the 2015 Plan, no further grants will be made under the 2008 Plan. The 2015 Plan provides for the granting of incentive stock options within the meaning of Section 422 of the Code to employees and the granting of non-qualified stock options to employees, non-employee directors and consultants. The 2015 Plan also provides for the grants of restricted stock, restricted stock units, stock appreciation rights, dividend equivalents and stock payments to employees, non-employee directors and consultants.

Under the 2015 Plan, the aggregate number of shares of the common stock authorized for issuance may not exceed (1) 54,200 plus (2) the sum of the number of shares subject to outstanding awards under the 2008 Plan as of the 2015 Plan’s effective date, that are subsequently forfeited or terminated for any reason before being exercised or settled, plus (3) the number of shares subject to vesting restrictions under the 2008 Plan as of the 2015 Plan’s effective date that are subsequently forfeited. In addition, the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors. Shares subject to awards granted under the 2015 Plan that are forfeited or terminated before being exercised or settled, or are not delivered to the participant because such award is settled in cash, will again become available for issuance under the 2015 Plan. However, shares that have actually been issued shall not again become available unless forfeited. As of June 30, 2019, 84,412 shares remain available for issuance under the 2015 Plan, which includes 345,828 shares automatically added to the 2015 Plan on January 1, 2019.

For the three and six months ended June 30, 2019 and 2018, the Company recognized stock-based compensation expense as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Cost of services	$	524	$	1,341	$	562	$	3,731
Research and development		18,333		61,080		35,460		130,551
General and administrative		61,365		140,158		137,378		292,340
Sales and marketing		5,749		11,311		10,604		25,458
	$	85,971	$	213,890	$	184,004	$	452,080

No income tax benefit for stock-based compensation arrangements was recognized in the condensed consolidated statements of operations and comprehensive loss due to the Company’s net loss position.

The Company did not grant any stock options during the three months ended June 30, 2019. During the three months ended June 30, 2019, 720 options were forfeited and no options expired. The Company did not grant any stock options during the six months ended June 30, 2019. During the six months ended June 30, 2019, 720 options were forfeited and 5 options expired. The Company had total stock options to acquire 210,834 shares of common stock outstanding at June 30, 2019.

Restricted stock units

During the six months ended June 30, 2019, 313,000 restricted stock units were granted, no restricted stock units vested and no restricted stock units were forfeited. The Company had 313,250 total restricted stock units outstanding at June 30, 2019.

Stock purchase warrants

At June 30, 2019 and December 31, 2018, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance	Exercise Price		Expiration	June 30, 2019		December 31, 2018
November 2009	$	197.75	November 2019		270		270
January 2010	$	197.75	January 2020		270		270
March 2010	$	197.75	March 2020		55		55
November 2011	$	197.75	November 2021		212		212
December 2011	$	197.75	December 2021		27		27
March 2012	$	2,747.50	March 2019		—		165
February 2015	$	165.00	February 2025		9,001		9,001
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.81	May 2021		189,577		189,577
June 2016	$	32.81	May 2021		82,035		82,035
June 2017	$	19.50	June 2022		18,754		18,754
July 2017	$	17.25	July 2022		6,350		6,350
July 2017	$	12.50	July 2022		50,000		50,000
July 2017	$	10.63	July 2022		1,000,003		1,000,003
February 2018	$	4.06	February 2023		184,615		184,615
February 2018	$	3.25	February 2023		1,846,153		1,846,153
					3,525,632		3,525,797

The warrants listed above were issued in connection with various debt, equity or development contract agreements.

Commitments

6 Months Ended

Jun. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments

Note 9 – Commitments

Registration and other stockholder rights

In connection with the various investment transactions, the Company entered into registration rights agreements with stockholders, pursuant to which the investors were granted certain demand registration rights and/or piggyback and/or resale registration rights in connection with subsequent registered offerings of the Company’s common stock.

Supply agreements

In June 2017, the Company entered into an agreement with Life Technologies Corporation (“LTC”) to supply the Company with QuantStudio 5 Real-Time PCR Systems (“QuantStudio 5”) to be used to run OpGen’s Acuitas AMR Gene Panel tests. Under the terms of the agreement, the Company must notify LTC of the number of QuantStudio 5s that it commits to purchase in the following quarter. As of June 30, 2019, the Company has acquired twenty-one QuantStudio 5s including six in the six months ended June 30, 2019. As of June 30, 2019, the Company has committed to acquiring an additional three QuantStudio 5s at a total cost of approximately $135,000 in the next three months.

Leases

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Leases

Note 10 – Leases

The following table presents the Company’s ROU assets and lease liabilities as of June 30, 2019:

Lease Classification	June 30, 2019
ROU Assets:
Operating	$	1,381,830
Financing		984,742
Total ROU assets	$	2,366,572
Liabilities
Current:
Operating	$	958,992
Finance		576,322
Noncurrent:
Operating		1,071,677
Finance		379,825
Total lease liabilities	$	2,986,816

Maturities of lease liabilities as of June 30, 2019 by fiscal year are as follows:

Maturity of Lease Liabilities	Operating			Finance			Total
2019	$	558,109		$	332,786		$	890,895
2020		1,128,138			520,947			1,649,085
2021		536,819			166,318			703,137
2022		40,080			11,240			51,320
2023		—			3,644			3,644
Thereafter		—			—			—
Total lease payments		2,263,146			1,034,935			3,298,081
Less: Interest		(232,477	)		(78,788	)		(311,265	)
Present value of lease liabilities	$	2,030,669		$	956,147		$	2,986,816

Statement of operations classification of lease costs are as follows:

		June 30, 2019
Lease Cost	Classification	Three months ended		Six months ended
Operating	Operating expenses	$	218,673	$	439,595
Finance:
Amortization	Operating expenses		107,496		204,689
Interest expense	Other expenses		19,297		41,778
Total lease costs		$	345,466	$	686,062

Other Information	Total
Weighted average remaining lease term (in years)
Operating leases		2.1
Finance leases		1.8
Weighted average discount rate:
Operating leases		10.0	%
Finance leases		9.2	%

Supplemental Cash Flow Information	Total
Cash paid for amounts included in the measurement of lease liabilities
Cash used in operating activities
Operating leases	$	439,595
Finance leases	$	41,778
Cash used in financing activities
Finance leases	$	235,600
ROU assets obtained in exchange for lease obligations:
Finance leases	$	355,536

Lease Commitments as of December 31, 2018

Minimum lease payments for future years as of December 31, 2018 were as follows:

Year ending December 31,	Total
2019	$	1,615,679
2020		1,534,204
2021		639,829
2022		40,080
2023 and thereafter		—
Total	$	3,829,792

License Agreements, Research Collaborations and Development Agreements

6 Months Ended

Jun. 30, 2019

License Agreements Research Collaborations And Development Agreements [Abstract]

License Agreements, Research Collaborations and Development Agreements

Note 11 – License agreements, research collaborations and development agreements

In 2018, the Company announced a collaboration with the New York State Department of Health (“DOH”) and ILÚM Health Solutions, LLC (“ILÚM”), a wholly-owned subsidiary of Merck’s Healthcare Services and Solutions division, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide. The Company is working together with DOH’s Wadsworth Center and ILÚM to develop an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance. As part of the collaboration, the Company will receive $1.6 million over the 12 month demonstration portion of the project. The demonstration project began in early 2019. During the three and six months ended June 30, 2019, the Company recognized $500,000 and $1.0 million of revenue related to the contract, respectively.

The Company is a party to one license agreement to acquire certain patent rights and technologies related to its FISH product line. Royalties are incurred upon the sale of a product or service which utilizes the licensed technology. The Company recognized net royalty expense of $62,500 for each of the three months ended June 30, 2019 and 2018. The Company recognized net royalty expense of $125,000 for each of the six months ended June 30, 2019 and 2018. Annual future minimum royalty fees are $250,000 under this agreement.

Related Party Transactions

6 Months Ended

Jun. 30, 2019

Related Party Transactions

Note 12 – Related party transactions

In October 2016, the Company entered into an agreement with Merck Sharp & Dohme Corp. (“MSD”), a wholly-owned subsidiary of Merck, and an affiliate of MGHIF, a principal stockholder of the Company and a related party to the Company. Under the agreement, MSD provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. MSD gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs. The Company is required to expend up to $175,000 for the procurement of materials related to the activities contemplated by the agreement. Contract life-to-date, the Company has incurred $171,646 of procurement costs which have been recognized as research and development expense. The Company recognized research and development expense of $0 and $22,604 related to the agreement in the three months ended June 30, 2019 and 2018, respectively. The Company recognized research and development expense of $0 and $22,604 related to the agreement in the six months ended June 30, 2019 and 2018, respectively.

In December 2017, the Company entered into a subcontractor agreement with ILÚM, whereby ILÚM will provide services to the Company in the performance of the Company’s CDC contract to deploy ILÚM’s commercially-available cloud- and mobile-based software platform for infectious disease management in up to three medical sites in Colombia with the aim of improving antibiotic use in resource-limited settings. The Company recognized $0 and $84,853 of cost of services expense related to the contract in the three months ended June 30, 2019 and 2018, respectively. The Company recognized $0 and $198,665 of cost of services expense related to the contract in the six months ended June 30, 2019 and 2018, respectively.

Summary of significant accounting policies (Policies)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Basis of presentation and consolidation

Foreign currency

Use of estimates

Fair value of financial instruments

Cash, cash equivalents and restricted cash

	June 30, 2019		December 31, 2018		June 30, 2018		December 31, 2017
Cash and cash equivalents	$	3,055,894	$	4,572,487	$	7,428,993	$	1,847,171
Restricted cash		185,380		164,720		181,490		243,380
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	$	3,241,274	$	4,737,207	$	7,610,483	$	2,090,551

Accounts receivable

Inventory

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials and supplies	$	237,500	$	368,438
Work-in-process		135,916		58,402
Finished goods		194,006		116,907
Total	$	567,422	$	543,747

Property and equipment

Leases

ROU assets

Intangible assets and goodwill

Intangible assets and goodwill as of June 30, 2019 consist of finite-lived intangible assets and goodwill.

Finite-lived intangible assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of June 30, 2019 and December 31, 2018:

			June 30, 2019					December 31, 2018
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and trade names	$	461,000	$	(182,835	)	$	278,165	$	(159,783	)	$	301,217
Developed technology		458,000		(259,458	)		198,542		(226,746	)		231,254
Customer relationships		1,094,000		(619,249	)		474,751		(541,105	)		552,895
	$	2,013,000	$	(1,061,542	)	$	951,458	$	(927,634	)	$	1,085,366

Goodwill

Revenue recognition

Deferred revenue results from amounts billed in advance to customers or cash received from customers in advance of services being provided.

Research and development costs

Stock-based compensation

Income taxes

Loss per share

Basic loss per share is computed by dividing net loss available to common stockholders by the weighted average number of shares of common stock outstanding during the period.

Accounting pronouncements adopted and not yet adopted

Adopted accounting pronouncements

•

The Company did not reassess if any expired or existing contracts are or contain leases.

•

The Company did not reassess the classification of any expired or existing leases.

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

	June 30, 2019		December 31, 2018		June 30, 2018		December 31, 2017
Cash and cash equivalents	$	3,055,894	$	4,572,487	$	7,428,993	$	1,847,171
Restricted cash		185,380		164,720		181,490		243,380
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	$	3,241,274	$	4,737,207	$	7,610,483	$	2,090,551

Schedule of Inventories

Inventories are valued using the first-in, first-out method and stated at the lower of cost or net realizable value and consist of the following:

	June 30, 2019		December 31, 2018
Raw materials and supplies	$	237,500	$	368,438
Work-in-process		135,916		58,402
Finished goods		194,006		116,907
Total	$	567,422	$	543,747

Schedule of Finite-Lived Intangible Assets

Finite-lived intangible assets include trademarks, developed technology and customer relationships and consisted of the following as of June 30, 2019 and December 31, 2018

			June 30, 2019					December 31, 2018
	Cost		Accumulated Amortization			Net Balance		Accumulated Amortization			Net Balance
Trademarks and trade names	$	461,000	$	(182,835	)	$	278,165	$	(159,783	)	$	301,217
Developed technology		458,000		(259,458	)		198,542		(226,746	)		231,254
Customer relationships		1,094,000		(619,249	)		474,751		(541,105	)		552,895
	$	2,013,000	$	(1,061,542	)	$	951,458	$	(927,634	)	$	1,085,366

Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2019

Revenue From Contract With Customer [Abstract]

Schedule of Revenues by Type of Service

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Product sales	$	504,293	$	632,525	$	1,024,470	$	1,266,021
Laboratory services		5,250		1,100		5,250		9,790
Collaboration revenue		500,000		155,276		1,000,000		359,316
Total revenue	$	1,009,543	$	788,901	$	2,029,720	$	1,635,127

Summary of Changes in Deferred Revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2018	$	15,824
Revenue recognized in the current period from the amounts in the beginning balance		(5,831	)
New deferrals, net of amounts recognized in the current period		—
Balance at June 30, 2019	$	9,993

Fair value measurements (Tables)

6 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table sets forth a summary of changes in the fair value of level 3 liabilities measured at fair value on a recurring basis for the six months ended June 30, 2019:

Description

Balance at

December 31,

2018

Change in

Fair Value

Balance at

June 30, 2019

Warrant liability

(67

)

—

Stockholders' equity (Tables)

6 Months Ended

Jun. 30, 2019

Stockholders Equity Note [Abstract]

Schedule of Company Recognized Stock-Based Compensation Expense

For the three and six months ended June 30, 2019 and 2018, the Company recognized stock-based compensation expense as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2019		2018		2019		2018
Cost of services	$	524	$	1,341	$	562	$	3,731
Research and development		18,333		61,080		35,460		130,551
General and administrative		61,365		140,158		137,378		292,340
Sales and marketing		5,749		11,311		10,604		25,458
	$	85,971	$	213,890	$	184,004	$	452,080

Schedule of Warrants to Purchase Shares of Common Stock

At June 30, 2019 and December 31, 2018, the following warrants to purchase shares of common stock were outstanding:

				Outstanding at
Issuance	Exercise Price		Expiration	June 30, 2019		December 31, 2018
November 2009	$	197.75	November 2019		270		270
January 2010	$	197.75	January 2020		270		270
March 2010	$	197.75	March 2020		55		55
November 2011	$	197.75	November 2021		212		212
December 2011	$	197.75	December 2021		27		27
March 2012	$	2,747.50	March 2019		—		165
February 2015	$	165.00	February 2025		9,001		9,001
May 2015	$	165.00	May 2020		138,310		138,310
May 2016	$	32.81	May 2021		189,577		189,577
June 2016	$	32.81	May 2021		82,035		82,035
June 2017	$	19.50	June 2022		18,754		18,754
July 2017	$	17.25	July 2022		6,350		6,350
July 2017	$	12.50	July 2022		50,000		50,000
July 2017	$	10.63	July 2022		1,000,003		1,000,003
February 2018	$	4.06	February 2023		184,615		184,615
February 2018	$	3.25	February 2023		1,846,153		1,846,153
					3,525,632		3,525,797

Leases (Tables)

6 Months Ended

Jun. 30, 2019

Leases [Abstract]

Schedule of ROU Assets and Lease Liabilities

The following table presents the Company’s ROU assets and lease liabilities as of June 30, 2019:

Lease Classification	June 30, 2019
ROU Assets:
Operating	$	1,381,830
Financing		984,742
Total ROU assets	$	2,366,572
Liabilities
Current:
Operating	$	958,992
Finance		576,322
Noncurrent:
Operating		1,071,677
Finance		379,825
Total lease liabilities	$	2,986,816

Schedule of Maturities of Lease Liabilities

Maturities of lease liabilities as of June 30, 2019 by fiscal year are as follows:

Maturity of Lease Liabilities	Operating			Finance			Total
2019	$	558,109		$	332,786		$	890,895
2020		1,128,138			520,947			1,649,085
2021		536,819			166,318			703,137
2022		40,080			11,240			51,320
2023		—			3,644			3,644
Thereafter		—			—			—
Total lease payments		2,263,146			1,034,935			3,298,081
Less: Interest		(232,477	)		(78,788	)		(311,265	)
Present value of lease liabilities	$	2,030,669		$	956,147		$	2,986,816

Schedule of Statement of Operations Classification of Lease Costs and Other Information

Statement of operations classification of lease costs are as follows:

		June 30, 2019
Lease Cost	Classification	Three months ended		Six months ended
Operating	Operating expenses	$	218,673	$	439,595
Finance:
Amortization	Operating expenses		107,496		204,689
Interest expense	Other expenses		19,297		41,778
Total lease costs		$	345,466	$	686,062

Other Information	Total
Weighted average remaining lease term (in years)
Operating leases		2.1
Finance leases		1.8
Weighted average discount rate:
Operating leases		10.0	%
Finance leases		9.2	%

Schedule of Supplemental Cash Flow Information

Supplemental Cash Flow Information	Total
Cash paid for amounts included in the measurement of lease liabilities
Cash used in operating activities
Operating leases	$	439,595
Finance leases	$	41,778
Cash used in financing activities
Finance leases	$	235,600
ROU assets obtained in exchange for lease obligations:
Finance leases	$	355,536

Schedule of Future Minimum Lease Payments

Minimum lease payments for future years as of December 31, 2018 were as follows:

Year ending December 31,	Total
2019	$	1,615,679
2020		1,534,204
2021		639,829
2022		40,080
2023 and thereafter		—
Total	$	3,829,792

Organization - Additional Information (Details)	6 Months Ended
Organization - Additional Information (Details)	Jun. 30, 2019 Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of operating business segment	1

Liquidity and Management's Plans - Additional Information (Details) - USD ($)								1 Months Ended	3 Months Ended	6 Months Ended		12 Months Ended
	Mar. 29, 2019	Oct. 22, 2018	Jul. 30, 2018	Jul. 14, 2018	Jun. 11, 2018	Feb. 06, 2018	Sep. 13, 2016	Jul. 31, 2015	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Conversion Of Stock [Line Items]
Proceeds from issuance of common stock, net of issuance costs										$ 4,782,509	$ 192,320
Net proceeds from sale of common stock and warrants										$ 0	$ 10,728,131
MGHIF Financing Agreement [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues								45,454
Shares issued, price per share								$ 110.00
Proceeds from issuance of common stock, net of issuance costs								$ 5,000,000
Aggregate principal amount								$ 1,000,000
MGHIF Financing Agreement [Member] \| The Allonge [Member]
Conversion Of Stock [Line Items]
Aggregate principal amount					$ 1,000,000
Accrued and unpaid interest				$ 285,512
Revised and extended maturity date for payment, terms					Six semi-annual payments
Principal payments includes accrued and unpaid interest					$ 166,667
Beginning date of debt maturity					Jan. 02, 2019
Ending date of debt maturity					Jul. 01, 2021
February 2018 Public Offering [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues						2,841,152
Shares issued, price per share						$ 3.25
Gross proceeds from sale of common stock and warrants						$ 12,000,000
Net proceeds from sale of common stock and warrants						$ 10,700,000
Sale of stock, description of transaction										Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.
Class of warrant or right, number of securities called by each warrant or right						0.5
Class of warrant or right, exercise price of warrants or rights						$ 3.25
Warrants exercisable period						5 years
At the Market Offering [Member]
Conversion Of Stock [Line Items]
Stock issued during period, value, new issues									$ 192,320
At the Market Offering [Member] \| Cowen and Company, LLC [Member] \| Sales Agreement [Member]
Conversion Of Stock [Line Items]
Gross proceeds from sale of common stock												$ 600,000
Proceeds from issuance of common stock, net of issuance costs												$ 600,000
Stock issued during period, value, new issues							$ 11,500,000
At the Market Offering [Member] \| Cowen and Company, LLC [Member] \| Sales Agreement [Member] \| Maximum [Member]
Conversion Of Stock [Line Items]
Aggregate gross proceeds from issuance of common stock							$ 25,000,000
Common Stock [Member] \| October 2018 Public Offering [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues		2,220,000
Shares issued, price per share		$ 1.45
Gross proceeds from sale of common stock		$ 3,200,000
Proceeds from issuance of common stock, net of issuance costs		$ 2,800,000
Common Stock [Member] \| March 2019 Public Offering [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues	9,000,000
Shares issued, price per share	$ 0.60
Gross proceeds from sale of common stock	$ 5,400,000
Proceeds from issuance of common stock, net of issuance costs	$ 4,800,000
Common Stock [Member] \| Private Placement [Member] \| MGHIF Financing Agreement [Member] \| The Allonge [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues			144,238
Accrued and unpaid interest			$ 285,512
Accrued and unpaid interest due date			Jul. 14, 2018
Common Stock [Member] \| At the Market Offering [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues									104,043
Stock issued during period, value, new issues									$ 1,040
Common Stock [Member] \| At the Market Offering [Member] \| Cowen and Company, LLC [Member] \| Sales Agreement [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues												318,236
Pre-funded Units [Member] \| February 2018 Public Offering [Member]
Conversion Of Stock [Line Items]
Stock issued during period, shares, new issues						851,155
Shares issued, price per share						$ 3.24
Pre-funded Warrants [Member] \| February 2018 Public Offering [Member]
Conversion Of Stock [Line Items]
Class of warrant or right, exercise price of warrants or rights						$ 0.01
Warrants exercised												851,155

Summary of Significant Accounting Policies - Additional Information (Details) shares in Millions	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019 USD ($) Customer	Jun. 30, 2018 USD ($) Customer	Jun. 30, 2019 USD ($) Customer shares	Jun. 30, 2018 USD ($) Customer shares	Dec. 31, 2018 USD ($) Customer	Jan. 01, 2019 USD ($)
Significant Accounting Policies [Line Items]
FDIC limit of insurable cash	$ 250,000		$ 250,000
Letters of credit outstanding, amount	185,380		185,380		$ 164,720
Allowance for doubtful accounts receivable	$ 22,309		$ 22,309		$ 18,332
Number of individual customers accounting for more than 10% of revenue \| Customer	1	1	1	1
Number of individual customers accounting for more than 10% of accounts receivable \| Customer	1		1		1
Inventory valuation reserves	$ 114,327		$ 114,327		$ 71,270
Amortization of intangible assets	66,954	$ 66,954	133,908	$ 133,908
Impairment of finite-lived intangible assets	0	0	0	0
Goodwill	600,814		600,814		600,814
Impairment of goodwill	0	$ 0	$ 0	$ 0
Antidilutive securities excluded from computation of earnings per share, amount \| shares			4.0	3.8
Operating lease right of use asset	1,381,830		$ 1,381,830		0	$ 2,200,000
Operating lease liability	$ 2,030,669		$ 2,030,669			$ 2,500,000
Domestic Country [Member]
Significant Accounting Policies [Line Items]
Operating loss carryforwards					$ 178,200,000
Operating loss carryforwards, expiration terms			begin to expire in 2022
Trademarks and Trade Names [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			10 years
Developed Technology [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years
Customer Relationships [Member]
Significant Accounting Policies [Line Items]
Finite-lived intangible asset, useful life			7 years
ASU 2016-02 [Member]
Significant Accounting Policies [Line Items]
Impairment charge			$ 520,759
Minimum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			30 days
Maximum [Member]
Significant Accounting Policies [Line Items]
Accounts receivable period due			60 days
Sales Revenue, Net [Member] \| Customer One [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage	50.00%	19.00%
Sales Revenue, Net [Member] \| Customer Two [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			49.00%	21.00%
Accounts Receivable [Member] \| Customer One [Member] \| Customer Concentration Risk [Member]
Significant Accounting Policies [Line Items]
Concentration risk, percentage			65.00%		12.00%

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash Cash Equivalents and Restricted Cash (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 3,055,894	$ 4,572,487	$ 7,428,993	$ 1,847,171
Restricted cash	185,380	164,720	181,490	243,380
Total cash, cash equivalents and restricted cash in the condensed consolidated statement of cash flows	$ 3,241,274	$ 4,737,207	$ 7,610,483	$ 2,090,551

Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Inventories
Raw materials and supplies	$ 237,500	$ 368,438
Work-in-process	135,916	58,402
Finished goods	194,006	116,907
Total	$ 567,422	$ 543,747

Summary of Significant Accounting Policies - Schedule of Finite-Lived Intangible Assets (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Cost	$ 2,013,000	$ 2,013,000
Accumulated Amortization	(1,061,542)	(927,634)
Net Balance	951,458	1,085,366
Trademarks and Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	461,000	461,000
Accumulated Amortization	(182,835)	(159,783)
Net Balance	278,165	301,217
Developed Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	458,000	458,000
Accumulated Amortization	(259,458)	(226,746)
Net Balance	198,542	231,254
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Cost	1,094,000	1,094,000
Accumulated Amortization	(619,249)	(541,105)
Net Balance	$ 474,751	$ 552,895

Revenue from Contracts with Customers - Schedule of Revenues by Type of Service (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Disaggregation Of Revenue [Line Items]
Total revenue	$ 1,009,543	$ 788,901	$ 2,029,720	$ 1,635,127
Product [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	504,293	632,525	1,024,470	1,266,021
Laboratory Services [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5,250	1,100	5,250	9,790
Collaboration Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 500,000	$ 155,276	$ 1,000,000	$ 359,316

Revenue from Contracts with Customers - Summary of Changes in Deferred Revenue (Details)	6 Months Ended
	Jun. 30, 2019 USD ($)
Revenue Recognition And Deferred Revenue [Abstract]
Balance at December 31, 2018	$ 15,824
Revenue recognized in the current period from the amounts in the beginning balance	(5,831)
Balance at June 30, 2019	$ 9,993

Revenue from Contracts with Customers - Additional Information (Details)	Jun. 30, 2019 USD ($)
Revenue From Contract With Customer [Abstract]
Contract with customers, asset	$ 0

Revenue from Contracts with Customers - Additional Information1 (Details) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2019-07-01	Jun. 30, 2019 USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Remaining contract consideration for which revenue has not been recognized due to unsatisfied performance obligations	$ 575,000
Remaining contract consideration, expected period to be recognized	6 months

MGHIF financing - Additional Information (Details) - USD ($)					1 Months Ended	6 Months Ended
	Jul. 30, 2018	Jul. 14, 2018	Jun. 11, 2018	Jun. 28, 2017	Jul. 31, 2015	Jun. 30, 2019	Jun. 30, 2018
Common Stock and Note Purchase Agreement [Line Items]
Proceeds from issuance of common stock, net of issuance costs						$ 4,782,509	$ 192,320
MGHIF Financing Agreement [Member]
Common Stock and Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues					45,454
Shares issued, price per share					$ 110.00
Proceeds from issuance of common stock, net of issuance costs					$ 5,000,000
Debt instrument, interest rate, stated percentage					8.00%
Debt instrument, face amount					$ 1,000,000
Unamortized debt issuance costs			$ 7,000
MGHIF Financing Agreement [Member] \| The Allonge [Member]
Common Stock and Note Purchase Agreement [Line Items]
Debt instrument, face amount			$ 1,000,000
Accrued and unpaid interest		$ 285,512
Revised and extended the maturity date, payment terms			Six semi-annual payments
Annual payments plus accrued and unpaid interest			$ 166,667
Beginning date of debt maturity			Jan. 02, 2019
Ending date of debt maturity			Jul. 01, 2021
MGHIF Financing Agreement [Member] \| The Allonge [Member] \| Common Stock [Member] \| Private Placement [Member]
Common Stock and Note Purchase Agreement [Line Items]
Stock issued during period, shares, new issues	144,238
Accrued and unpaid interest	$ 285,512
Stock issued during period, accrued and unpaid interest due	$ 285,512
Accrued and unpaid interest due date	Jul. 14, 2018
Amended and Restated MGHIF Financing Agreement [Member]
Common Stock and Note Purchase Agreement [Line Items]
Debt instrument, interest rate, stated percentage				10.00%
Debt instrument, extended maturity date				Jul. 14, 2018
Issuance of common stock warrants to purchase				13,120

Fair value measurements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets transferred between fair value measurement levels			$ 0
Fair Value on Non-Recurring Basis [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Financial assets measured at fair value	$ 0		0
Financial liabilities measured at fair value	0		0
Impairment of non-financial assets and liabilities at fair value	0	$ 0	0	$ 0
Fair Value on Recurring Basis [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-financial assets measured at fair value	0		0
Non-financial liabilities measured at fair value	$ 0		$ 0

Fair value measurements - Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Warrant Liability [Member]	6 Months Ended
	Jun. 30, 2019 USD ($)
Changes in the fair value of Level 3 liabilities measured at fair value on recurring basis
Balance at the beginning of the period	$ 67
Change in Fair Value	(67)
Balance at the end of the period	$ 0

Debt - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
Debt - Additional Information (Details) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Debt Instrument [Line Items]
Short-term debt	$ 343,330		$ 343,330		$ 398,595
Interest expense, debt	37,129	$ 54,533	93,573	$ 112,379
Due in 2019 [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment	333,000		333,000
Due in 2020 [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment	333,000		333,000
Due in 2021 [Member]
Debt Instrument [Line Items]
Debt instrument, annual principal payment	333,000		333,000
MGHIF Financing Agreement [Member]
Debt Instrument [Line Items]
Short-term debt	333,000		333,000		333,000
Long-term debt, outstanding	495,000		495,000		660,000
Notes Payable, Other Payables [Member]
Debt Instrument [Line Items]
Short-term debt	$ 10,000		$ 10,000		$ 65,000

Stockholders' Equity - Additional Information (Details) - USD ($)						3 Months Ended		6 Months Ended		12 Months Ended
	Mar. 29, 2019	Jan. 01, 2019	Oct. 22, 2018	Feb. 06, 2018	Sep. 13, 2016	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares authorized						50,000,000		50,000,000		50,000,000
Common stock, shares issued						17,645,720		17,645,720		8,645,720
Common stock, shares outstanding						17,645,720		17,645,720		8,645,720
Preferred stock, shares authorized						10,000,000		10,000,000		10,000,000
Preferred stock, shares issued						0		0		0
Preferred stock, shares outstanding						0		0		0
Proceeds from issuance of common stock, net of issuance costs								$ 4,782,509	$ 192,320
Net proceeds from sale of common stock and warrants								0	$ 10,728,131
Stock-based compensation, tax benefit from compensation expense								$ 0
Stock options, granted						0		0
Stock options, forfeited						720		720
Stock options, outstanding						210,834		210,834
Stock options, expired						0		5
Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period								313,000
Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested in period								0
Share-based compensation arrangement by share-based payment award, equity instruments other than options, forfeited in period								0
Share-based compensation arrangement by share-based payment award, equity instruments other than options, non-vested, outstanding						313,250		313,250
2015 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized						54,200		54,200
Share-based compensation arrangement by share-based payment award, description								the number of shares that have been authorized for issuance under the 2015 Plan will be automatically increased on the first day of each fiscal year beginning on January 1, 2016 and ending on (and including) January 1, 2025, in an amount equal to the lesser of (1) 4% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year, or (2) another lesser amount determined by the Company’s Board of Directors.
Share-based compensation arrangement by share-based payment award, number of shares available for grant						84,412		84,412
Share-based compensation arrangement by share-based payment award, common stock percentage								4.00%
Share-based compensation arrangement by share-based payment award, number of additional shares added		345,828
At the Market Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues							$ 192,320
At the Market Offering [Member] \| Sales Agreement [Member] \| Cowen and Company, LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues					$ 11,500,000
Proceeds from issuance of common stock, net of issuance costs										$ 600,000
Gross proceeds from sale of common stock										$ 600,000
At the Market Offering [Member] \| Sales Agreement [Member] \| Maximum [Member] \| Cowen and Company, LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Aggregate gross proceeds from issuance of common stock					$ 25,000,000
At the Market Offering [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, value, new issues							$ 1,040
Stock issued during period, shares, new issues							104,043
At the Market Offering [Member] \| Common Stock [Member] \| Sales Agreement [Member] \| Cowen and Company, LLC [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues										318,236
February 2018 Public Offering [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues				2,841,152
Shares issued, price per share				$ 3.25
Gross proceeds from sale of common stock and warrants				$ 12,000,000
Net proceeds from sale of common stock and warrants				$ 10,700,000
Sale of stock, description of transaction								Each unit included one share of common stock and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share. Each pre-funded unit included one pre-funded warrant to purchase one share of common stock for an exercise price of $0.01 per share, and one common warrant to purchase 0.5 share of common stock at an exercise price of $3.25 per share.
Class of warrant or right, number of securities called by each warrant or right				0.5
Class of warrant or right, exercise price of warrants or rights				$ 3.25
Warrants exercisable period				5 years
February 2018 Public Offering [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights				$ 4.0625
Warrants exercisable period				5 years
February 2018 Public Offering [Member] \| Common Stock [Member] \| Placement Agent [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock warrants to purchase				184,615
February 2018 Public Offering [Member] \| Pre-funded Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues				851,155
Shares issued, price per share				$ 3.24
February 2018 Public Offering [Member] \| Pre-funded Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, exercise price of warrants or rights				$ 0.01
Warrants exercised										851,155
October 2018 Public Offering [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues			2,220,000
Proceeds from issuance of common stock, net of issuance costs			$ 2,800,000
Gross proceeds from sale of common stock			$ 3,200,000
Shares issued, price per share			$ 1.45
March 2019 Public Offering [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock issued during period, shares, new issues	9,000,000
Proceeds from issuance of common stock, net of issuance costs	$ 4,800,000
Gross proceeds from sale of common stock	$ 5,400,000
Shares issued, price per share	$ 0.60

Stockholders' Equity - Company Recognized Stock-Based Compensation Expense (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 85,971	$ 213,890	$ 184,004	$ 452,080
Cost of Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	524	1,341	562	3,731
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	18,333	61,080	35,460	130,551
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	61,365	140,158	137,378	292,340
Sales and Marketing [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated share-based compensation expense	$ 5,749	$ 11,311	$ 10,604	$ 25,458

Stockholders' Equity - Warrants to Purchase Shares of Common Stock (Details) - $ / shares	6 Months Ended
	Jun. 30, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of Common Stock Subject to Warrants	3,525,632	3,525,797
November 2009 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75
Expiration	2019-11
Shares of Common Stock Subject to Warrants	270	270
January 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75
Expiration	2020-01
Shares of Common Stock Subject to Warrants	270	270
March 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75
Expiration	2020-03
Shares of Common Stock Subject to Warrants	55	55
November 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75
Expiration	2021-11
Shares of Common Stock Subject to Warrants	212	212
December 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 197.75
Expiration	2021-12
Shares of Common Stock Subject to Warrants	27	27
March 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 2,747.50
Expiration	2019-03
Shares of Common Stock Subject to Warrants		165
February 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 165.00
Expiration	2025-02
Shares of Common Stock Subject to Warrants	9,001	9,001
May 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 165.00
Expiration	2020-05
Shares of Common Stock Subject to Warrants	138,310	138,310
May 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 32.81
Expiration	2021-05
Shares of Common Stock Subject to Warrants	189,577	189,577
June 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 32.81
Expiration	2021-05
Shares of Common Stock Subject to Warrants	82,035	82,035
June 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 19.50
Expiration	2022-06
Shares of Common Stock Subject to Warrants	18,754	18,754
July 2017 [Member] \| Exercise Price 17.25 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 17.25
Expiration	2022-07
Shares of Common Stock Subject to Warrants	6,350	6,350
July 2017 [Member] \| Exercise Price 12.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 12.50
Expiration	2022-07
Shares of Common Stock Subject to Warrants	50,000	50,000
July 2017 [Member] \| Exercise Price 10.63 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 10.63
Expiration	2022-07
Shares of Common Stock Subject to Warrants	1,000,003	1,000,003
February 2018 [Member] \| Exercise Price 4.06 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 4.06
Expiration	2023-02
Shares of Common Stock Subject to Warrants	184,615	184,615
February 2018 [Member] \| Exercise Price 3.25 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise Price	$ 3.25
Expiration	2023-02
Shares of Common Stock Subject to Warrants	1,846,153	1,846,153

Commitments - Additional Information (Details) - QuantStudio 5 Real-Time PCR Systems [Member] - Life Technologies Corporation Supply Agreement [Member] $ in Thousands		6 Months Ended
	Jun. 30, 2019 USD ($) Product	Jun. 30, 2019 USD ($) Product
Other Commitments [Line Items]
Number of products acquired	21
Number of products acquired during period		6
Committed to acquire total cost of additional products in next three months \| $	$ 135,000	$ 135,000
Number of products committed to be acquired		3

Leases - Schedule of ROU Assets and Lease Liabilities (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
ROU Assets:
Operating	$ 1,381,830	$ 2,200,000	$ 0
Financing	984,742		0
Total ROU assets	2,366,572
Current:
Operating	958,992		0
Finance	576,322		399,345
Noncurrent:
Operating	1,071,677		0
Finance	379,825		$ 437,189
Total lease liabilities	$ 2,986,816

Leases - Schedule of Maturities of Lease Liabilities (Details) - USD ($)	Jun. 30, 2019	Jan. 01, 2019
Operating
2019	$ 558,109
2020	1,128,138
2021	536,819
2022	40,080
Total lease payments	2,263,146
Less: Interest	(232,477)
Present value of lease liabilities	2,030,669	$ 2,500,000
Finance
2019	332,786
2020	520,947
2021	166,318
2022	11,240
2023	3,644
Total lease payments	1,034,935
Less: Interest	(78,788)
Present value of lease liabilities	956,147
Total
2019	890,895
2020	1,649,085
2021	703,137
2022	51,320
2023	3,644
Total lease payments	3,298,081
Less: Interest	(311,265)
Present value of lease liabilities	$ 2,986,816

Leases - Schedule of Statement of Operations Classification of Lease Costs (Details) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019
Lease Cost
Total lease costs	$ 345,466	$ 686,062
Operating Expense [Member]
Lease Cost
Operating	218,673	439,595
Amortization	107,496	204,689
Other Expense [Member]
Lease Cost
Interest expense	$ 19,297	$ 41,778

Leases - Schedule of Other Information (Details)	Jun. 30, 2019
Weighted average remaining lease term (in years)
Operating leases	2 years 1 month 6 days
Finance leases	1 year 9 months 18 days
Weighted average discount rate:
Operating leases	10.00%
Finance leases	9.20%

Leases - Schedule of Supplemental Cash Flow Information (Details) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash used in operating activities
Operating leases	$ 439,595
Finance leases	41,778
Cash used in financing activities
Finance leases	235,600	$ 107,871
ROU assets obtained in exchange for lease obligations
Finance leases	$ 355,536

Leases - Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2018 USD ($)
Leases [Abstract]
2019	$ 1,615,679
2020	1,534,204
2021	639,829
2022	40,080
Total	$ 3,829,792

License Agreements, Research Collaborations and Development Agreements - Additional Information (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2019 USD ($) Agreement	Jun. 30, 2018 USD ($)	Jun. 30, 2019 USD ($) Agreement	Jun. 30, 2018 USD ($)
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract	$ 1,009,543	$ 788,901	$ 2,029,720	$ 1,635,127
Royalty expense	62,500	62,500	125,000	125,000
Annual future minimum royalty payments due	250,000		250,000
Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract	$ 500,000	$ 155,276	$ 1,000,000	$ 359,316
FISH Product Line [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Number of license agreements \| Agreement	1		1
New York State Department of Health and ILÚM Health Solutions, LLC [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Collaboration revenue receivable over 12 months of the project	$ 1,600,000		$ 1,600,000
Contractual agreement period			12 months
New York State Department of Health and ILÚM Health Solutions, LLC [Member] \| Collaborations Revenue [Member]
License Agreements Research Collaborations And Development Agreements [Line Items]
Revenue from contract	$ 500,000		$ 1,000,000

Related Party Transactions - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		32 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Oct. 31, 2016
Service [Member]
Related Party Transaction [Line Items]
Cost of services	$ 251,981	$ 179,402	$ 396,463	$ 347,955
Merck Sharp & Dohme Corp [Member]
Related Party Transaction [Line Items]
Research and development agreement description			Under the agreement, MSD provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. MSD gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs.
Maximum required amount to expend for procurement of materials						$ 175,000
Merck Sharp & Dohme Corp [Member] \| Research and Development Expense [Member]
Related Party Transaction [Line Items]
Procurement costs recognized	0	22,604	$ 0	22,604	$ 171,646
ILÚM Health Solutions, LLC [Member] \| Subcontractor Agreement [Member] \| Service [Member]
Related Party Transaction [Line Items]
Cost of services	$ 0	$ 84,853	$ 0	$ 198,665